Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN&sup2 ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners.

Evotec and Novo Nordisk launched LAB eN² in September 2023 with four academic institutions, Harvard University, Mass General Brigham, Yale School of Medicine, and Beth Israel Deaconess Medical ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture ...

“We are thrilled to be able to start work on these first projects, leveraging Evotec’s integrated drug discovery and translational platforms and Novo Nordisk’s deep disease understanding,” said Dr ...

Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk 11.12.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement.

"We are thrilled to be able to start work on these first projects, leveraging Evotec's integrated drug discovery and translational platforms and Novo Nordisk's deep disease understanding," said ...